

Combined Photodynamic Therapy with Intravitreal Bevacizumab for Neovascular ARMD

Authors: Young Ju Lew, Moon Jung Choi, Tae Gon Lee, Sung Won Cho, (Kim,'s Eye Hospital, Konyang Universtiy, Seoul, Korea), Eun Jee Chung (NHIC, Ilsan Hospital, Gyunggido, Korea), Sung Woo Ha (Bungdang CHA General Hospital, Pochun CHA University, Guyunggido, Korea)

Advantages:

To investigate the efficacy of combined treatment of photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab in patients with neovascular age-related macular degeneration. To achieve better visual outcomes and reduce the rate of reinjections when compared to the intravitreal bevacizumab monotherapy.

Methods:

Forty-five eyes received a single session of PDT following 3 intravitreal bevacizumab (1.25mg) injections at 6 week interval (IVB + PDT group). 27 eyes received 3 intravitreal bevacizumab (1.25mg) injections only every 6 weeks (IVB group).

Effectiveness / Safety:

Significant improvements in visual acuity and reduction in central macular thickness over a 6-month period were observed in both groups. The average vision was significantly better and the rate of reinjections after the initial treatment schedule was lower in IVB + PDT group.